Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Cash from Operations (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Cash from Operations for 7 consecutive years, with 7911000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Cash from Operations rose 33.15% year-over-year to 7911000.0, compared with a TTM value of 22699000.0 through Dec 2019, up 55.91%, and an annual FY2024 reading of 70760000.0, down 111.48% over the prior year.
  • Cash from Operations was 7911000.0 for Q4 2019 at Larimar Therapeutics, down from 5823000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3506000.0 in Q2 2019 and bottomed at 17944000.0 in Q4 2015.
  • Average Cash from Operations over 5 years is 11474950.0, with a median of 11961000.0 recorded in 2017.
  • The sharpest move saw Cash from Operations crashed 175.8% in 2015, then soared 126.34% in 2019.
  • Year by year, Cash from Operations stood at 17944000.0 in 2015, then skyrocketed by 51.71% to 8666000.0 in 2016, then fell by 13.5% to 9836000.0 in 2017, then dropped by 20.31% to 11834000.0 in 2018, then surged by 33.15% to 7911000.0 in 2019.
  • Business Quant data shows Cash from Operations for LRMR at 7911000.0 in Q4 2019, 5823000.0 in Q3 2019, and 3506000.0 in Q2 2019.